R Kahn1, J Buse, E Ferrannini, M Stern. 1. American Diabetes Association, 1701 N. Beauregard Street, Alexandria, VA 22311, USA. rkahn@diabetes.org
Abstract
BACKGROUND: The term 'metabolic syndrome' refers to a clustering of specific cardiovascular disease (CVD) risk factors whose underlying pathophysiology is thought to be related to insulin resistance. METHODS: Since the term is widely used in research and clinical practice, we undertook an extensive review of the literature in relation to the syndrome's definition, underlying pathogenesis, association with cardiovascular disease and to the goals and impact of treatment. DISCUSSION: While there is no question that certain CVD risk factors are prone to cluster, we found that the metabolic syndrome has been imprecisely defined, there is a lack of certainty regarding its pathogenesis, and there is considerable doubt regarding its value as a CVD risk marker. Our analysis indicates that too much critically important information is missing to warrant its designation as a 'syndrome'. CONCLUSION: Until much-needed research is completed, clinicians should evaluate and treat all CVD risk factors without regard to whether a patient meets the criteria for diagnosis of the 'metabolic syndrome'.
BACKGROUND: The term 'metabolic syndrome' refers to a clustering of specific cardiovascular disease (CVD) risk factors whose underlying pathophysiology is thought to be related to insulin resistance. METHODS: Since the term is widely used in research and clinical practice, we undertook an extensive review of the literature in relation to the syndrome's definition, underlying pathogenesis, association with cardiovascular disease and to the goals and impact of treatment. DISCUSSION: While there is no question that certain CVD risk factors are prone to cluster, we found that the metabolic syndrome has been imprecisely defined, there is a lack of certainty regarding its pathogenesis, and there is considerable doubt regarding its value as a CVD risk marker. Our analysis indicates that too much critically important information is missing to warrant its designation as a 'syndrome'. CONCLUSION: Until much-needed research is completed, clinicians should evaluate and treat all CVD risk factors without regard to whether a patient meets the criteria for diagnosis of the 'metabolic syndrome'.
Authors: A Festa; R D'Agostino; L Mykkänen; R P Tracy; D J Zaccaro; C N Hales; S M Haffner Journal: Arterioscler Thromb Vasc Biol Date: 1999-03 Impact factor: 8.311
Authors: T A Hillier; A Rousseau; C Lange; P Lépinay; M Cailleau; M Novak; E Calliez; P Ducimetière; B Balkau Journal: Diabetologia Date: 2006-05-16 Impact factor: 10.122
Authors: N Siitonen; L Pulkkinen; U Mager; J Lindström; J G Eriksson; T T Valle; H Hämäläinen; P Ilanne-Parikka; S Keinänen-Kiukaanniemi; J Tuomilehto; M Laakso; M Uusitupa Journal: Diabetologia Date: 2006-05-25 Impact factor: 10.122
Authors: Fernando Perez-Ruiz; Maria Angeles Aniel-Quiroga; Ana María Herrero-Beites; Sandra Pamela Chinchilla; Gorka Garcia Erauskin; Toni Merriman Journal: Rheumatol Int Date: 2015-03-13 Impact factor: 2.631
Authors: R K Simmons; K G M M Alberti; E A M Gale; S Colagiuri; J Tuomilehto; Q Qiao; A Ramachandran; N Tajima; I Brajkovich Mirchov; A Ben-Nakhi; G Reaven; B Hama Sambo; S Mendis; G Roglic Journal: Diabetologia Date: 2009-12-11 Impact factor: 10.122
Authors: Anna Viitasalo; Timo A Lakka; David E Laaksonen; Kai Savonen; Hanna-Maaria Lakka; Maija Hassinen; Pirjo Komulainen; Tuomo Tompuri; Sudhir Kurl; Jari A Laukkanen; Rainer Rauramaa Journal: Diabetologia Date: 2014-01-24 Impact factor: 10.122